Recombinant multi-species MAP4K4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MAP4K4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase has been shown to specifically activate MAPK8/JNK. The activation of MAPK8 by this kinase is found to be inhibited by the dominant-negative mutants of MAP3K7/TAK1, MAP2K4/MKK4, and MAP2K7/MKK7, which suggests that this kinase may function through the MAP3K7-MAP2K4-MAP2K7 kinase cascade, and mediate the TNF-alpha signaling pathway. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 9430080K19Rik,FLH21957,HEL-S-31,HGK,HPK/GCK-like kinase HGK,MAP4K4,MAPK/ERK kinase kinase kinase 4 (MEK kinase kinase 4,MEKKK 4),MEKKK4,Map4k4,Mitogen-activated protein kinase kinase kinase kinase 4,NIK,Nck-interacting kinase,Nik

Target products collectionGo to MAP4K4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T71367-Ag-1/ GM-Tg-hg-T71367-Ag-2 Human MAP4K4 protein Human
GM-Tg-rg-T71367-Ag-1/ GM-Tg-rg-T71367-Ag-2 Rat MAP4K4 protein Rat
GM-Tg-mg-T71367-Ag-1/ GM-Tg-mg-T71367-Ag-2 Mouse MAP4K4 protein Mouse
GM-Tg-cynog-T71367-Ag-1/ GM-Tg-cynog-T71367-Ag-2 Cynomolgus/Rhesus macaque MAP4K4 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T71367-Ag-1/ GM-Tg-felg-T71367-Ag-2 Feline MAP4K4 protein Feline
GM-Tg-cang-T71367-Ag-1/ GM-Tg-cang-T71367-Ag-2 Canine MAP4K4 protein Canine
GM-Tg-bovg-T71367-Ag-1/ GM-Tg-bovg-T71367-Ag-2 Bovine MAP4K4 protein Bovine
GM-Tg-equg-T71367-Ag-1/ GM-Tg-equg-T71367-Ag-2 Equine MAP4K4 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T71367-Ag-1/ GM-Tg-hg-T71367-Ag-2; GM-Tg-rg-T71367-Ag-1/ GM-Tg-rg-T71367-Ag-2;
GM-Tg-mg-T71367-Ag-1/ GM-Tg-mg-T71367-Ag-2; GM-Tg-cynog-T71367-Ag-1/ GM-Tg-cynog-T71367-Ag-2;
GM-Tg-felg-T71367-Ag-1/ GM-Tg-felg-T71367-Ag-2; GM-Tg-cang-T71367-Ag-1/ GM-Tg-cang-T71367-Ag-2;
GM-Tg-bovg-T71367-Ag-1/ GM-Tg-bovg-T71367-Ag-2; GM-Tg-equg-T71367-Ag-1/ GM-Tg-equg-T71367-Ag-2
Products Name MAP4K4 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name MAP4K4
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MAP4K4 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.